565456-74-8

Basic information

• Product Name: Cyclobutanepropanoic acid, α-amino-, ethyl ester, hydrochloride
• Synonyms: Cyclobutanepropanoic acid, α-amino-, ethyl ester, hydrochloride;Ethyl 2-amino-3-cyclobutylpropanoate hydrochloride;RS-Cyclobutylalanine ethyl ester hydrochloride
• CAS NO: 565456-74-8
• Molecular Formula: C9H17NO2 . ClH
• Molecular Weight: 207.7
• Mol File: 565456-74-8.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Cyclobutanepropanoic acid, α-amino-, ethyl ester, hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclobutanepropanoic acid, α-amino-, ethyl ester, hydrochloride(565456-74-8)
• EPA Substance Registry System: Cyclobutanepropanoic acid, α-amino-, ethyl ester, hydrochloride(565456-74-8)

Safety Data

• Hazardous Substances Data: 565456-74-8(Hazardous Substances Data)

Usage

General Description

Cyclobutanepropanoic acid, α-amino-, ethyl ester, hydrochloride is a chemical compound that is derived from α-amino-cyclobutyric acid, an amino acid analog. It is commonly used as a research tool in the study of neurotransmission and synaptic plasticity due to its potential as a GABA receptor agonist. Cyclobutanepropanoic acid, α-amino-, ethyl ester, hydrochloride has been found to have anticonvulsant and anxiolytic properties, making it a potential candidate for the development of new therapeutic drugs for epilepsy and anxiety disorders. The hydrochloride form of the compound is commonly used as a stable and water-soluble salt for experimental and research purposes. Its pharmacological effects and mechanisms of action make it a promising target for further investigation and drug development in the field of neurological and psychiatric disorders.

Upstream product

• 17247-58-4 (Bromomethyl)cyclobutane 
• 69555-14-2 ethyl N-diphenylmethylene glycine 
• 394735-17-2 ethyl 2-amino-3-cyclobutylpropanoate 
• 1025799-39-6 2-(benzhydrylidene-amino)-3-cyclobutyl-propionic acid ethyl ester 
• 40718-32-9 2-(benzhydrylamino)acetic acid ethyl ester 

Downstream Products

• 816430-02-1 ethyl 2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoate 

Relevant articles and documents

Pharmaceutical formulations and methods of treatment using the same

Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.

Methods for treating hepatitis C

Methods of treating hepatitis C are provided comprising using a therapeutically effective amount of at least one novel hepatitis C (“HCV”) protease inhibitor or, alternatively, at least one antiviral or immuno-modulating HCV agent, which is not an HCV protease inhibitor, for a first treatment period. Subsequently, a combination of the at least one novel hepatitis C (“HCV”) protease inhibitor and the at least one antiviral or immuno-modulating HCV agent are administered in a therapeutically effective amount for a second treatment period. The methods are provided for treating a wide variety of diseases, disorders and symptoms associated with hepatitis C virus by modulating the activity of HCV protease (for example HCV NS3/NS4a serine protease) in a subject.

ASYMMETRIC DOSING METHODS

A method of treating, preventing or ameliorating one or more symptoms of hepatitis C, or inhibiting cathepsin activity, in a subject is provided, in which at least one compound (e.g., a HCV protease inhibitor) is administered in one or more discrete dosages over a twenty-four hour time interval in an asymmetric pattern as to dosage amount and/or timing of dosage, wherein the at least one compound is selected from the group consisting of compounds of Formulae I-XXVI, described herein. Methods of modulating the activity of hepatitis C virus protease in a subject are also provided. Asymmetric dosing as to amount of dose and/or timing of dose permits adjustment of dosing to accommodate variations in drug metabolism and/or viral activity caused by viral cell division or a patient's circadian rhythms, thus delivering the maximum amount of dose at the time or times it is most effective.